Traders should monitor for any upcoming earnings releases or clinical trial updates that may have prompted this monetization. The absence of purchases and concentration of sales among executives may signal lack of near-term conviction, especially given elevated stock price (~$80). Consider this a cautionary signal ahead of potential volatility.
Price Chart
Executive Summary
Kymera Therapeutics COO Chadwick Jeremy G conducted a series of derivative exercises and open-market sales over the past week, generating approximately $3.73 million in proceeds from the sale of 47,483 shares. Director Pamela Esposito also sold 700 shares for $54,400, following option exercises. The activity is concentrated among senior insiders, with the majority of economic impact coming from open-market sales.
Key Financial Metrics
Key Facts
- COO Chadwick Jeremy G sold 47,483 shares in open-market transactions for total proceeds of ~$3.73M ($1.98M on March 25 at $80.26, $1.75M on March 23 at $76.73).
- All sales were preceded by derivative (option) exercises; some at $0 cost basis indicate incentive grants being monetized.
- Director Pamela Esposito sold 700 shares for $54,400 following exercise of 2,500 options at $49.10 strike price.
- Total open-market sale value from cluster: ~$3.79M (including prior 30-day activity), representing 0.06% of $6.1B market cap — modest in scale but notable due to C-suite participation.
- No open-market purchases or insider buying activity observed.
Financial Impact
$3.79M in insider sales over 7 days, with $3.73M from COO alone; represents 0.06% of market cap
Risk Factors
- Perception of insider pessimism due to lack of offsetting buys and timing of sales at current price levels.
- Potential for further selling if other insiders follow suit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-KYMR-1774473338973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access